Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu Pharmaceutical Technology Co., Ltd, a China-based company previously established as a wholly foreign-owned enterprise (WFOE) by Hong Kong WD Pharmaceutical Co., Ltd. The financial details of the agreement have not been disclosed.
This collaboration aims to capitalize on Handu Pharma’s AcuSiS technology platform to explore a new oral administration mode, designed to alleviate the challenges of swallowing medication faced by children and elderly patients, enhance medication adherence in drug development and clinical use, and embody a patient-centered approach to drug development.
AcuSiS is a versatile technology platform developed by Handu Pharma, capable of accommodating various dosage forms including particles, pellets, and tablets. It offers high flexibility and can be integrated into oral solid drug delivery devices to address both swallowing and palatability concerns. The AcuSiS drug dispenser is characterized by its ease of use without the need for preparation, and its concealed administration features, which can help to alleviate patients’ apprehension towards medication and improve compliance.- Flcube.com
